OA-25 Evaluation of a Vision-Related Anamnestic Tool (VRAT) to Guide Belantamab Mafodotin Dosing With Bortezomib and Dexamethasone for Multiple Myeloma: Interim Results From the UKMRA ProMMise D Trial

IF 4.1 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2026-09-01 Epub Date: 2026-09-22 DOI:10.1016/S2152-2650(26)03326-4

Rakesh Popat, Alexandra Welsh, Andrew Hall, Ceri Bygrave, Dean Smith, Simona Esposti, Frank Larkin, Gordon Cook, Matthew W. Jenner, Martin Kaiser, Lydia Lee, Sylvia Feyler, Anastascia Chew, Adam Forbes, Edward Belsham, Victoria Peacock, Izabelle Wood, Heena Patel, Laura Clayton, Sadie Roberts, Charlotte Pawlyn

引用次数: 0

查看原文本刊更多论文

OA-25评估视力相关记忆工具（VRAT）指导贝兰他单抗马弗多汀与硼替佐米和地塞米松联合治疗多发性骨髓瘤：来自UKMRA承诺D试验的中期结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.